
Benzinga Pro data, Ocular Therapeutix (NASDAQ:OCUL) reported Q4 sales of $12.31 million. Earnings fell to a loss of $3.85 million, resulting in a 244.9% decrease from last quarter. Ocular Therapeutix reached earnings of $2.66 million and sales of $12.15 million in Q3.